NRXS | NeurAxis, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.4901 - 2.7000
52 Week Range	2.0000 - 3.89
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	21,451
Average Volume	23,896
Shares Outstanding	6,980,230
Market Cap	18,846,621
Sector	Healthcare
Industry	Biotechnology
IPO Date	2023-08-09

Valuation
Profitability
Growth
Health
P/E Ratio	-6.75
Forward P/E Ratio	N/A
EPS	-0.40
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	19
Country	USA
Website	NRXS

NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

*Chart delayed

Analyzing fundamentals for NRXS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see NRXS Fundamentals page.

Watching at NRXS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on NRXS Technicals page.